SSEA-4 Antibody (MC813): sc-59368

SSEA-4 Antibody (MC813) is a mouse monoclonal IgG3 antibody that detects SSEA-4 in mouse, rat, and human samples through immunofluorescence (IF) and flow cytometry (FCM) applications. SSEA-4 is a crucial marker for identifying undifferentiated embryonic stem cells and embryonic germ cells, playing a significant role in stem cell research and regenerative medicine. This glycosphingolipid is primarily located on the cell surface, where SSEA-4 contributes to the maintenance of pluripotency and self-renewal capabilities of stem cells. SSEA-4 expression is typically lost upon differentiation, making SSEA-4 essential for distinguishing between differentiated and undifferentiated cells. Furthermore, SSEA-4 interacts with various lectins and antibodies, which can be utilized in cell sorting and characterization studies, making SSEA-4 a valuable tool for researchers investigating stem cell biology and developmental processes. Anti-SSEA-4 antibody (MC813) is particularly effective in identifying and isolating stem cells, thereby facilitating advancements in therapeutic applications and tissue engineering.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

SSEA-4 Antibody (MC813) References:

1. mTORC1 maintains the tumorigenicity of SSEA-4(+) high-grade osteosarcoma.  |  Zhang, W., et al. 2015. Sci Rep. 5: 9604. PMID: 25853231
2. SSEA-4 and YKL-40 positive progenitor subtypes in the subventricular zone of developing human neocortex.  |  Brøchner, CB. and Møllgård, K. 2016. Glia. 64: 90-104. PMID: 26295543
3. Aberrant SSEA-4 upregulation mediates myofibroblast activity to promote pre-cancerous oral submucous fibrosis.  |  Yu, CC., et al. 2016. Sci Rep. 6: 37004. PMID: 27845370
4. The role of Globo H and SSEA-4 in the development and progression of cancer, and their potential as therapeutic targets.  |  Sigal, DS., et al. 2022. Future Oncol. 18: 117-134. PMID: 34734786
5. Homogeneous antibody and CAR-T cells with improved effector functions targeting SSEA-4 glycan on pancreatic cancer.  |  Lin, CW., et al. 2021. Proc Natl Acad Sci U S A. 118: PMID: 34876527
6. SSEA-4 positive dental pulp stem cells from deciduous teeth and their induction to neural precursor cells.  |  Lopez-Lozano, AP., et al. 2022. Head Face Med. 18: 9. PMID: 35236383
7. Targeting Stage-Specific Embryonic Antigen 4 (SSEA-4) in Triple Negative Breast Cancer by CAR T Cells Results in Unexpected on Target/off Tumor Toxicities in Mice.  |  Pfeifer, R., et al. 2023. Int J Mol Sci. 24: PMID: 37298141
8. Efficacy and Safety of Glycosphingolipid SSEA-4 Targeting CAR-T Cells in an Ovarian Carcinoma Model.  |  Monzo, HJ., et al. 2023. Mol Cancer Ther. 22: 1319-1331. PMID: 37486980
9. Increased expression of SSEA-4 on TKI-resistant non-small cell lung cancer with EGFR-T790M mutation.  |  Chen, NY., et al. 2024. Proc Natl Acad Sci U S A. 121: e2313397121. PMID: 38252815
10. Development of Subcutaneous SSEA3- or SSEA4-Positive Cell Capture Device.  |  Nakayama, Y. and Iwai, R. 2024. Bioengineering (Basel). 11: PMID: 38927821

The preferred SSEA-4 antibody is SSEA-4 Antibody (813-70): sc-21704.